La dinámica del virus de la hepatitis C entre los consumidores de drogas intravenosas sugiere que un tratamiento anual superior a 10% eliminaría la enfermedad para 2030
Summary Background and Aims In Switzerland, the prevalence of hepatitis C virus (HCV) among people who inject drugs (PWID) has been decreasing owing to active harm reduction efforts and an aging population. Recent advances in HCV therapeutics may provide an opportunity to direct treatment to high-risk populations, with a goal of reducing HCV prevalence and […]
Spanish 
English 
French 
Russian 
Arabic